First Trust Advisors
KLRS

First Trust Advisors’s Kalaris Therapeutics KLRS Stock Holding History

First Trust Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,949
Closed -$2.61M – 2472
2020
Q4 		$2.61M Buy
+2,949
New +$2.27M ﹤0.01% 1448

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

First Trust Advisors's KLRS Position: Q1 2021 in Review

First Trust Advisors sold out of Kalaris Therapeutics (KLRS) in Q1 2021, closing a stake of 2,949 shares — an estimated $2.61M sold.

First Trust Advisors first reported a position in KLRS in Q4 2020 and held it in 1 quarter. The position peaked at $2.61M in Q4 2020. 75 funds tracked by Wall St. Rank hold KLRS as of Q1 2021.

  • First Trust Advisors reported no remaining Kalaris Therapeutics position as of Q1 2021 after selling out during the quarter.
  • First Trust Advisors sold 2,949 Kalaris Therapeutics shares in Q1 2021, an estimated $2.61M.
  • First Trust Advisors first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 1 quarter.
  • First Trust Advisors's Kalaris Therapeutics position peaked at $2.61M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2021.

Based on First Trust Advisors's 13F filing for Q1 2021, filed 14 May 2021.